Physician

Adam S. Kittai, M.D.

According to 2025 Medicare claims, Adam Kittai, M.D. (NPI: 1417214974) practices hematology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (NPI: 1750649612; TIN: 611661781) and primary practice location at 10029-6501. Kittai is affiliated with the CVS ACO (ACO ID: A5407) and CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under both the MSSP and REACH models.

Kittai's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 107 traditional Medicare patients, billed 299 HCPCS/CPT codes, and received $23,292 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 252 prescription claims across 42 beneficiaries totaling $3,163,283 in drug costs, led by Calquence (Acalabrutinib Maleate). Open Payments data shows 44 records totaling $3,933,354. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,708 to $3,163,283. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	56	180	$16,502
2020	133	364	$32,065
2021	197	591	$55,113
2022	169	494	$44,771
2023	191	489	$45,323
2024	107	299	$23,292

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	43	$1,708
2016	N/R	17	$2,838
2017	N/R	15	$925
2018	N/R	N/R	N/R
2019	N/R	28	$169,697
2020	16	125	$1,239,686
2021	33	243	$2,648,571
2022	43	292	$3,375,957
2023	50	357	$4,536,458
2024	42	252	$3,163,283

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	16	18	$145
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	45	76	$101
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	18	71	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	30	30	$50
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	54	70	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	139	4,170	$2,073,627
Venclexta	Venetoclax	34	1,004	$460,148
Imbruvica	Ibrutinib	28	784	$438,702
Brukinsa	Zanubrutinib	12	360	$186,099

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$9,633	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$3,923,721	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam S. Kittai, M.D.?

Tedicare shows public-source Medicare data for Adam S. Kittai, M.D. (NPI 1417214974), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam S. Kittai, M.D. have ACO affiliation data?

Adam S. Kittai, M.D. is shown with ACO affiliation data for CVS ACO (MSSP, ACO ID A5407) and CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Adam S. Kittai, M.D.?

Adam S. Kittai, M.D. is linked to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (billing NPI 1750649612) in the available physician profile data.

Does Adam S. Kittai, M.D. have Open Payments data?

Adam S. Kittai, M.D. has 44 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.